ChemoCentryx, Inc.

2014 Q3 Form 10-Q Financial Statement

#000119312514302705 Filed on August 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.30M $99.90M $129.8M
YoY Change -31.49% -23.04% -1.37%
Cash & Equivalents $20.90M $13.11M $50.28M
Short-Term Investments $64.40M $86.80M $79.50M
Other Short-Term Assets $800.0K $900.0K $1.000M
YoY Change 33.33% -10.0% -23.08%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $900.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $86.07M $100.8M $131.7M
YoY Change -31.49% -23.44% -1.15%
LONG-TERM ASSETS
Property, Plant & Equipment $1.193M $1.241M $1.220M
YoY Change -17.15% 1.72% -6.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $39.40M $33.30M $36.60M
YoY Change 20.49% -9.02% 565.45%
Other Assets $200.0K $182.0K $160.0K
YoY Change 25.0% 13.75% -20.0%
Total Long-Term Assets $40.76M $34.75M $37.99M
YoY Change 18.72% -8.53% 442.7%
TOTAL ASSETS
Total Short-Term Assets $86.07M $100.8M $131.7M
Total Long-Term Assets $40.76M $34.75M $37.99M
Total Assets $126.8M $135.5M $169.7M
YoY Change -20.71% -20.11% 21.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.030M $690.0K $1.198M
YoY Change 48.84% -42.4% -29.53%
Accrued Expenses $7.050M $7.130M $5.543M
YoY Change 40.89% 28.63% 15.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $100.0K $500.0K
YoY Change -100.0% -80.0% 0.0%
Total Short-Term Liabilities $8.127M $7.925M $8.732M
YoY Change 25.32% -9.24% -24.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% -85.71%
Other Long-Term Liabilities $189.0K $192.0K $240.0K
YoY Change -14.86% -20.0% -85.88%
Total Long-Term Liabilities $189.0K $192.0K $240.0K
YoY Change -14.86% -20.0% -90.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.127M $7.925M $8.732M
Total Long-Term Liabilities $189.0K $192.0K $240.0K
Total Liabilities $8.316M $8.117M $9.103M
YoY Change 22.85% -10.83% -34.04%
SHAREHOLDERS EQUITY
Retained Earnings -$207.6M -$196.7M -$153.9M
YoY Change 27.11% 27.8%
Common Stock $43.00K $43.00K $43.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $118.5M $127.4M $160.6M
YoY Change
Total Liabilities & Shareholders Equity $126.8M $135.5M $169.7M
YoY Change -20.71% -20.11% 21.01%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43335756 shares
CY2012Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
150000 shares
CY2012Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
20.00
CY2013Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.00
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50278000
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43335756 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43335756 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2014Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Investment
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.31
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7045255 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1832262 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1700000 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7130000
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
277000
CY2014Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
324040000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
690000
CY2014Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
422000
CY2014Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
0
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7925000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1342000
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
192000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
127429000
CY2014Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
105000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196660000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135546000
CY2014Q2 us-gaap Liabilities
Liabilities
8117000
CY2014Q2 us-gaap Long Term Investments
LongTermInvestments
33324000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
100799000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
182000
CY2014Q2 us-gaap Assets
Assets
135546000
CY2014Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
131382000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13107000
CY2014Q2 us-gaap Short Term Investments
ShortTermInvestments
86799000
CY2014Q2 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2014Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
131382000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
893000
CY2014Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2014Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
131359000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1977347
CY2014Q2 us-gaap Cash
Cash
1800000
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18000000
CY2014Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11259000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1241000
CY2014Q2 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2014Q2 ccxi Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
27000
CY2014Q2 ccxi Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments
0
CY2014Q2 ccxi Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
50000
CY2014Q2 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
5089000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42888168 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42888168 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5301622 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2383920 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5649000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318103000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
909000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
399000
CY2013Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6872000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1589000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
226000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
145308000
CY2013Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
314000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172862000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152422000
CY2013Q4 us-gaap Liabilities
Liabilities
7114000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
123055000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
393000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
147828000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
596000
CY2013Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
147788000
CY2013Q4 us-gaap Cash
Cash
2000000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
16561000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
134302000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q4 us-gaap Assets
Assets
152422000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
147828000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10258000
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8212000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1399000
CY2013Q4 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2013Q4 ccxi Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
26000
CY2013Q4 ccxi Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
66000
CY2013Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
3337000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38974000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18280000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5025194 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
364000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-254000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19863000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3813000
us-gaap Investment Income Interest
InvestmentIncomeInterest
226000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-166000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
283000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19891000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
92045000
us-gaap Interest Paid
InterestPaid
16000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
194000
us-gaap Net Income Loss
NetIncomeLoss
-19697000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2299000
us-gaap Costs And Expenses
CostsAndExpenses
23704000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5773000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
66693000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2257000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
us-gaap Share Based Compensation
ShareBasedCompensation
3094000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41818000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6595000
us-gaap Interest Expense
InterestExpense
32000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64365000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17931000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-798000
us-gaap Depreciation
Depreciation
283000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
85532000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
757000
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2414935 shares
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Description of Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemoattractant receptor-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Unaudited Interim Financial Information</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#xA0;31, 2013 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s financial statements and the notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#xA0;31, 2013 filed with the Securities and Exchange Commission on March&#xA0;14, 2014.</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M10D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43191000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.63
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16433000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2279800 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
163277 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
372890 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain items in the notes to Condensed Consolidated Financial Statements have been reclassified to conform to the current fiscal year&#x2019;s format.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7350985 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div>
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
297000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-393000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23816000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
275000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
22000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-18000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
225000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24056000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
62641000
us-gaap Interest Paid
InterestPaid
64000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
258000
us-gaap Net Income Loss
NetIncomeLoss
-23798000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
127000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1648000
us-gaap Costs And Expenses
CostsAndExpenses
24056000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6905000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1423000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Share Based Compensation
ShareBasedCompensation
4289000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2849000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17859000
us-gaap Interest Expense
InterestExpense
17000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-219000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17151000
ccxi Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
0 shares
CY2012Q1 ccxi Warrant Contractual Term
WarrantContractualTerm
P10Y
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64400000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41337000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9661000
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1886000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
110000
CY2013Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-157000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9599000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
95000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-9504000
CY2013Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
11485000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1494000
us-gaap Depreciation
Depreciation
285000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
80627000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1442000
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionForfeited
163277 shares
ccxi Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
Less than two years
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2809000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2013Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2013Q2 us-gaap Interest Expense
InterestExpense
15000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8676000
CY2013Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43274000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12297000
CY2014Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
129000
CY2014Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-36000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12384000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
123000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-12261000
CY2014Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
12384000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3382000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2200000
CY2014Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2014Q2 us-gaap Interest Expense
InterestExpense
6000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9002000
CY2014Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q2 ccxi Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares

Files In Submission

Name View Source Status
0001193125-14-302705-index-headers.html Edgar Link pending
0001193125-14-302705-index.html Edgar Link pending
0001193125-14-302705.txt Edgar Link pending
0001193125-14-302705-xbrl.zip Edgar Link pending
ccxi-20140630.xml Edgar Link completed
ccxi-20140630.xsd Edgar Link pending
ccxi-20140630_cal.xml Edgar Link unprocessable
ccxi-20140630_def.xml Edgar Link unprocessable
ccxi-20140630_lab.xml Edgar Link unprocessable
ccxi-20140630_pre.xml Edgar Link unprocessable
d727126d10q.htm Edgar Link pending
d727126dex101.htm Edgar Link pending
d727126dex311.htm Edgar Link pending
d727126dex312.htm Edgar Link pending
d727126dex321.htm Edgar Link pending
d727126dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending